![]() Flotufolastat F-18 gallium | |
Clinical data | |
---|---|
Trade names | Posluma |
Other names | 18F-rhPSMA-7.3 |
License data | |
Routes of administration | Intravenous |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem CID | |
DrugBank | |
UNII | |
KEGG | |
Chemical and physical data | |
3D model (JSmol) | |
| |
|
Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer.[1] The active ingredient is flotufolastat F-18 gallium.[1]
Flotufolastat F-18 was approved for medical use in the United States in May 2023.[1][2]
Flotufolastat F-18 is indicated for positron emission tomography of prostate-specific membrane antigen positive lesions in men with prostate cancer.[1][3]